Search results for "Preserved ejection fraction"

showing 3 items of 43 documents

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine

2021

Heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) constitute two heart failure categories, representing about 50–70% of the total [...]

medicine.medical_specialtyanimal structuresEjection fractionbusiness.industry05 social sciencesRGeneral Medicine030204 cardiovascular system & hematologymedicine.diseasePrecision medicine03 medical and health sciencesEditorialn/a0302 clinical medicineInternal medicineHeart failure0502 economics and businessCardiologymedicineMedicine050211 marketingbusinessHeart failure with preserved ejection fractionJournal of Clinical Medicine
researchProduct

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

2021

BACKGROUND Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet b-blockers are commonly used in HFpEF despite the lack of robust evidence. OBJECTIVES This study aimed to evaluate the effect of b-blocker withdrawal on peak oxygen consumption (peak VO2) in patients with HFpEF and chronotropic incompetence. METHODS This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with b-bloc…

medicine.medical_specialtyanimal structuresEjection fractionpeak Vo2chronotropic incompetencebusiness.industryChronotropic incompetencepercentage of predicted peakVo2Exercise capacitymedicine.diseaseHFpEFCrossover studyHeart failureInternal medicineHeart ratemedicineCardiologyβ-blockersheart ratecrossover trialCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusiness
researchProduct

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct